FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Maravai LifeSciences Holdings FCF Yield % Related Terms
Maravai LifeSciences Holdings FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MRVI vs LBRX, SLDB, JANX: FCF Yield % Comparison
For the Biotechnology subindustry, Maravai LifeSciences Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maravai LifeSciences Holdings (MEX:MRVI) has a FCF Yield % of -5.75 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Maravai LifeSciences Holdings and its competitors. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #565 out of 1415 companies in the Biotechnology industry, placing it in the top 39.9%.
Is Maravai LifeSciences Holdings' FCF Yield % too high?
Maravai LifeSciences Holdings' current FCF Yield % is -5.75. Based on the distribution chart, Maravai LifeSciences Holdings ranks #565 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' FCF Yield % compare to LBRX and SLDB?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #565 out of 1415 companies for FCF Yield %. This puts Maravai LifeSciences Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Maravai LifeSciences Holdings and its competitors. Maravai LifeSciences Holdings's current FCF Yield % is -5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Maravai LifeSciences Holdings (MEX:MRVI) has a current FCF Yield % of -5.75. The stock's GF Value™ is MXN52.37, compared to a current price of MXN85.00 — trading 62.3% above its estimated fair value. The current FCF Yield % is -5.75. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MEX:MRVI), the current FCF Yield % is -5.75 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MEX:MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of MXN85.00 is trading 62.3% above its estimated GF Value™ of MXN52.37.
Key valuation signals for MEX:MRVI:
FCF Yield %: -5.75
GF Value™: MXN52.37 vs. price of MXN85.00 (62.3% above fair value)
No single metric tells the full story. See the MEX:MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Business Description
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score
Get the complete analysis for MEX:MRVI
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MRVI has been successfully added to your 
